Advertisement

Interférences avec l’axe corticotrope

  • D. Annane
  • V. Maxime
  • H. Prigent
Part of the Le point sur⋯ book series (POINT)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Orth DN, Kovacs WJ, DeBold CR (1992) The Adrenal Cortex. In: Wilson JD, Foster DW (ed) Williams Textbook of Endocrinology, W. B. Saunders Company, Philadelphia. p 489–531Google Scholar
  2. 2.
    Almawi WY (2001) Molecular Mechanisms of Glucocorticoid Effects. Mod Asp Immunobiol 2(2): 78–82Google Scholar
  3. 3.
    Chrousos GP (1995) The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 332(20): 1351–62CrossRefPubMedGoogle Scholar
  4. 4.
    Cavaillon JM (2000) Rôle des glucocorticoïdes dans la cascade inflammatoire. Réanim Urgences 9: 605–12Google Scholar
  5. 5.
    Tsigos C, Chrousos GP (2002) Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res 53(4): 865–71CrossRefPubMedGoogle Scholar
  6. 6.
    Marik PE, Zaloga GP (2002) Adrenal insufficiency in the critically ill: a new look at an old problem. Chest 122(5): 1784–96CrossRefPubMedGoogle Scholar
  7. 7.
    Pilkis SJ, Granner DK (1992) Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Ann Rev Physiol 54: 885–909Google Scholar
  8. 8.
    Chrousos GP (2000) The Stress Response and Immune Function: Clinical Implications. The 1999 Novera H. Spector Lecture. In: Conti A, Maestroni JM, McCann SM, Sternberg EM, Lipton JM, Smith CC (ed) Neuroimmunomodulation. Perspectives at the New Millennium, Ann N Y Acad Sci, New York. p 38–67Google Scholar
  9. 9.
    Beishuizen A, Thijs LG, Haanen C, Vermes I (2001) Macrophage migration inhibitory factor and hypothalamo-pituitary-adrenal function during critical illness. J Clin Endocrinol Metab 86(6): 2811–6CrossRefPubMedGoogle Scholar
  10. 10.
    Beishuizen A, Vermes I, Hylkema BS, Haanen C (1999) Relative eosinophilia and functional adrenal insufficiency in critically ill patients. Lancet 353(9165): 1675–6CrossRefPubMedGoogle Scholar
  11. 11.
    Keh D, Boehnke T, Weber-Cartens S et al. (2003) Immunologic and hemodynamic effects of «low-dose» hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 167(4): 512–20CrossRefPubMedGoogle Scholar
  12. 12.
    Beishuizen A, Thijs LG (2003) Endotoxin and the hypothalamo-pituitary-adrenal (HPA) axis. J Endotoxin Res 9(1): 3–24CrossRefPubMedGoogle Scholar
  13. 13.
    Soni A, Pepper GM, Wyrwinski PM et al. (1995) Adrenal insufficiency occurring during septic shock: incidence, outcome, and relationship to peripheral cytokine levels. Am J Med 98(3):266–71CrossRefPubMedGoogle Scholar
  14. 14.
    Franchimont D, Martens H, Hagelstein MT et al. (1999) Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor. J Clin Endocrinol Metab 84(8): 2834–9CrossRefPubMedGoogle Scholar
  15. 15.
    Muller B, Peri G, Doni A et al. (2002) High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol 72(4):643–9PubMedGoogle Scholar
  16. 16.
    Briegel J, Kellermann W, Forst H et al. (1994) Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. The Phospholipase A2 Study Group. Clin Investig 72(10): 782–7CrossRefPubMedGoogle Scholar
  17. 17.
    Annane D, Bellissant E (2002) Impact des corticoiïdes sur la réponse vasomotrice aux catécholamines dans le choc septique. Réanimation 11: 111–6Google Scholar
  18. 18.
    Lamberts SW, Bruining HA, de Jong FH (1997) Corticosteroid therapy in severe illness. N Engl J Med 337(18): 1285–92CrossRefPubMedGoogle Scholar
  19. 19.
    Beishuizen A, Thijs LG, Vermes I (2001) Patterns of corticosteroid-binding globulin and the free cortisol index during septic shock and multitrauma. Intensive Care Med 27(10): 1584–91CrossRefPubMedGoogle Scholar
  20. 20.
    Schroeder S, Wichers M, Klingmuller D et al. (2001) The hypothalamic-pituitary-adrenal axis of patients with severe sepsis: altered response to corticotropin-releasing hormone. Crit Care Med 29(2): 310–6PubMedGoogle Scholar
  21. 21.
    Mastorakos G, Chrousos GP, Weber JS (1993) Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 77(6): 1690–4CrossRefPubMedGoogle Scholar
  22. 22.
    Streeten DH (1999) What test for hypothalamic-pituitary-adrenocortical insufficiency? Lancet 354(9174): 179–80CrossRefPubMedGoogle Scholar
  23. 23.
    Jurney TH, Cockrell JL Jr, Lindberg JS et al. (1987) Spectrum of serum cortisol response to ACTH in ICU patients. Correlation with degree of illness and mortality. Chest 92(2): 292–5PubMedGoogle Scholar
  24. 24.
    Loisa P, Rinne T, Kaukinen S (2002) Adrenocortical function and multiple organ failure in severe sepsis. Acta Anaesthesiol Scand 46(2): 145–51CrossRefPubMedGoogle Scholar
  25. 25.
    Span LF, Hermus AR, Bartelink AK et al. (1992) Adrenocortical function: an indicator of severity of disease and survival in chronic critically ill patients. Intensive Care Med 18(2): 93–6CrossRefPubMedGoogle Scholar
  26. 26.
    Schein RM, Sprung CL, Marcial E et al. (1990) Plasma cortisol levels in patients with septic shock. Crit Care Med 18(3): 259–63PubMedGoogle Scholar
  27. 27.
    Rothwell PM, Lawler PG (1995) Prediction of outcome in intensive care patients using endocrine parameters. Crit Care Med 23(1): 78–83PubMedGoogle Scholar
  28. 28.
    Chernow B, Alexander HR, Smallridge RC et al. (1987) Hormonal responses to graded surgical stress. Arch Intern Med 147(7):1273–8CrossRefPubMedGoogle Scholar
  29. 29.
    Rothwell PM, Udwadia ZF, Lawler PG (1991) Cortisol response to corticotropin and survival in septic shock. Lancet 337(8741): 582–3CrossRefPubMedGoogle Scholar
  30. 30.
    Annane D, Sebille V, Troche G et al. (2000) A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. Jama 283(8): 1038–45CrossRefPubMedGoogle Scholar
  31. 31.
    The Veterans Administration Systemic Sepsis Cooperative Study Group (1987) Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 317(11):659–65Google Scholar
  32. 32.
    Bone RC, Fisher CJ, Jr., Clemmer TP et al. (1987) A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317(11): 653–8PubMedGoogle Scholar
  33. 33.
    Cronin L, Cook DJ, Carlet J et al. (1995) Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 23(8): 1430–9PubMedGoogle Scholar
  34. 34.
    Annane D, Raphael JC, Gajdos P (1996) Are endogenous glucocorticoid levels adequate in septic shock? Intensive Care Med 22(7):711–2CrossRefPubMedGoogle Scholar
  35. 35.
    Marik PE, Zaloga GP (2003) Adrenal insufficiency during septic shock. Crit Care Med 31(1):141–5PubMedGoogle Scholar
  36. 36.
    Moran JL, Chapman MJ, O’Fathartaigh MS et al. (1994) Hypocortisolaemia and adrenocortical responsiveness at onset of septic shock. Intensive Care Med 20(7): 489–95CrossRefPubMedGoogle Scholar
  37. 37.
    Briegel J, Schelling G, Haller M et al. (1996) A comparison of the adrenocortical response during septic shock and after complete recovery. Intensive Care Med 22(9):894–9PubMedGoogle Scholar
  38. 38.
    Barber AE, Coyle SM, Marano MA et al. (1993) Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol 150(5):1999–2006PubMedGoogle Scholar
  39. 39.
    Bhagat K, Collier J, Vallance P (1996) Local venous responses to endotoxin in humans. Circulation 94(3): 490–7PubMedGoogle Scholar
  40. 40.
    Annane D, Sebille V, Charpentier C et al. (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288(7): 862–71CrossRefPubMedGoogle Scholar
  41. 41.
    Briegel J, Forst H, Haller M et al. (1999) Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 27(4): 723–32PubMedGoogle Scholar
  42. 42.
    Bollaert PE, Charpentier C, Levy B et al. (1998) Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 26(4): 645–50PubMedGoogle Scholar
  43. 43.
    Bellissant E, Annane D (2000) Effect of hydrocortisone on phenylephrine—mean arterial pressure dose-response relationship in septic shock. Clin Pharmacol Ther 68(3):293–303CrossRefPubMedGoogle Scholar
  44. 44.
    Annane D, Bellissant E, Sebille V et al. (1998) Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. Br J Clin Pharmacol 46(6): 589–97CrossRefPubMedGoogle Scholar
  45. 45.
    Hotchkiss RS, Karl IE (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348(2): 138–50CrossRefPubMedGoogle Scholar
  46. 46.
    McKee JI, Finlay WE (1983) Cortisol replacement in severely stressed patients. Lancet 1(8322): 484PubMedGoogle Scholar

Copyright information

© Springer-Verlag France 2005

Authors and Affiliations

  • D. Annane
  • V. Maxime
  • H. Prigent

There are no affiliations available

Personalised recommendations